STAT3 and cancer: Together with our in silico STAT-SH2 docking studies of selected non-specific STAT3 inhibitors (Figure 3), we propose their potential of targeting cooperative involvement of NF-κB, STATs, and IRFs (on ISRE, GAS, ISRE/GAS, ISRE/NF-κB or GAS/NF-κB binding sites: see Figure 2) in regulation of crucial pro-inflammatory and pro-atherogenic target genes as a novel clinical application in CVDs apart from their established role in cancer treatment and prevention.